Physician profile
Michael Yap
NPI 1588847362
$3,505.17
in general payments reported to CMS, 2019-2025
21 companies · $14.03 in 2025
The $14.03 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,254 · 2020: $1,129 · 2021: $548 · 2022: $389 · 2023: $68.16 · 2024: $102 · 2025: $14.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $184.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, INC. | $717.50 | 2020 | |
| Vifor Pharma, INC. | $590.25 | 2019-2024 | Veltassa |
| Otsuka America Pharmaceutical, INC. | $495.18 | 2019-2022 | |
| Akebia Therapeutics INC | $237.72 | 2019-2020 | |
| Opko Pharmaceuticals, LLC | $153.77 | 2019-2025 | Rayaldee |
| Veloxis Pharmaceuticals, INC. | $145.96 | 2019-2022 | |
| Fresenius USA Marketing, INC. | $140.67 | 2019-2024 | Velphoro |
| Amgen INC. | $138.34 | 2019-2021 | |
| Boston Scientific Corporation | $118.01 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.84 | 2021-2022 | |
| La Jolla Pharmaceutical Company | $116.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $112.97 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $109.11 | 2019 | |
| Mallinckrodt Hospital Products INC. | $75.45 | 2020-2022 | |
| Baxter Healthcare | $72.15 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Calliditas Therapeutics US INC. | $48.35 | 2022 | |
| Alexion Pharmaceuticals, INC. | $29.20 | 2019 | |
| Alnylam Pharmaceuticals INC. | $22.62 | 2021 | |
| Eurofins Viracor, LLC | $22.23 | 2021 | |
| Horizon Therapeutics Plc | $21.28 | 2019 | |
| Aurinia Pharma U.S., INC. | $21.07 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Yap listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.